Compare EYPT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYPT | ABEO |
|---|---|---|
| Founded | 1987 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.3M | 282.5M |
| IPO Year | 2005 | 2005 |
| Metric | EYPT | ABEO |
|---|---|---|
| Price | $0.23 | $2.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 7 |
| Target Price | $8.31 | ★ $15.56 |
| AVG Volume (30 Days) | ★ 5.8M | 2.2M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | $2,998,000.00 |
| Revenue This Year | N/A | $675.42 |
| Revenue Next Year | N/A | $126.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $0.26 | $2.09 |
| 52 Week High | $19.11 | $7.65 |
| Indicator | EYPT | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 16.61 | 27.49 |
| Support Level | N/A | $2.09 |
| Resistance Level | $3.57 | $5.77 |
| Average True Range (ATR) | 0.04 | 0.32 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 2.11 | 15.88 |
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.